Rectal Cancer
Conditions
Keywords
Resectable rectal cancer, Radiotherapy, Bevacizumab, Capecitabine
Brief summary
The purpose of the study is to evaluate the efficacy and safety of the combination of capecitabine + bevacizumab concomitantly with radiotherapy versus capecitabine concomitantly with radiotherapy, as neoadjuvant treatment for patients with localized and resectable rectal cancer.
Interventions
DRUGBevacizumab + Capecitabine + Radiotherapy
Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
Sponsors
Hoffmann-La Roche
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent * Age ≥18 years * ECOG ≤ 1 * Histologically confirmed carcinoma of the rectum * Localized and resectable rectal cancer * No metastatic disease * Measurable disease * Life expectancy more than 4 months * Non prior treatment for rectal cancer * Adequate haematological function: leu ≥ 4x 109 /l, Hb ≥10 gr/dl, neutropils≥ 1,5 x 109 /l and platelets ≥100 x 109 /l * Adequate renal function: creatinine ≤ 106 umol/l or calculated creatinine clearance \> 50 mL/min * Adequate liver function: AST, ALT and alkaline phosphatase ≤2.5 x UL, bilirubin ≤1.5 x UL * Adequate nutritional weight loss \<10% of regular weight and albumin ≥ 35 g/l
Exclusion criteria
* Unresectable rectal cancer * Past or current history (within the last 5 years prior to treatment start) of other malignancies. * Patients of childbearing potential not willing to use effective means of contraception. * Clinically significant cardiovascular disease * Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take oral medication. * Patients subjected to organ allografts who require immunosuppressive treatment. * Severe, non-cicatrized osseous fractures, wounds or ulcers. * Indications of hemorrhagic diathesis or coagulopathy. * Severe, uncontrolled intercurrent infections or other severe, uncontrolled concomitant diseases. * History of unexpected severe reactions to treatment with fluoropyrimidines or known deficiency dihydropyrimidine dehydrogenase deficiency (DPD). * Patients subjected to a major surgical procedure, open biopsy or who have had significant traumatic lesions within the 28 days prior to beginning the treatment of the study or in whom it is foreseen that a major surgical procedure will be necessary during the course of the study; fine-needle aspiration within the 7 days prior to beginning the treatment of the study. * Current or recent use (within the 10 days prior to beginning the treatment of the study) of oral or parenteral anticoagulants at complete doses or thrombolytic agents. The use of low doses of warfarin is allowed, with an International Normalized Ratio \[INR\] of \< 1.5. * Daily chronic treatment with high doses of aspirin (\> 325 mg/day) or non-steroid anti-inflammatory medications (which inhibit the platelet function at doses used for treating chronic inflammatory diseases). * Patients who have received any drug or agent/procedure under research, i.e., who have participated in another clinical trial during the 4 weeks prior to beginning the treatment with the medications of the study * Any psychological, familiar conditions suggesting that the patient will not be able to complete the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate complete pathologic responses | 17 months |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival at 3 and 5 years | 78 months |
| Overall survival at 3 and 5 years | 78 months |
| Rate of local and distant recurrence at 3 and 5 years | 78 months |
| R0 resection rate. | 17 months |
| Adverse events | 17 months |
| Rate of surgery complications | 17 months |
| Molecular predictive markers: changes in angiogenic parameters, vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptors, microvessel quantification and angiopoietin-2 (Ang-2) | 17 months |
| Rate of sphincter preservation | 17 months |
Countries
Spain
Outcome results
None listed